At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
CK-1827452 +2 moredrug
Likely dose
CK-1827452 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Investigate the Pharmacokinetics of CK-1827452 Administered Orally to Patients With Stable Heart Failure
In Brief
A Phase 2 clinical trial evaluating CK-1827452 for Heart Failure. Completed, enrolled 35 participants across 3 sites.
Detailed Summary
This study is designed to understand the pharmacokinetics of different oral formulations of CK-1827452 being considered for future studies in patients with heart failure. This study will compare the pharmacokinetics and safety and tolerability of both modified-release (MR) and immediate-release (IR) oral formulations of CK-1827452.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesGeorgia
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJul 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedJul 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.0 years ago
Interventions
CK-1827452drug
50 mg MR CK-1827452 BID for 10 days
CK-1827452drug
37.5 mg IR CK-1827452 TID for 10 days
CK-1827452drug
100 mg MR CK-1827452 BID for 10 days